|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Limbic-predominant age-related TAR-DNA-binding protein-43 (TDP-43) encephalopathy with hippocampal sclerosis pathology (LATE-NC + HS) is a neurodegenerative disorder characterized by severe hippocampal CA1 neuron loss and TDP-43-pathology, leading to cognitive dysfunction and dementia.
|
31376286 |
2020 |
|
Hippocampal sclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Main differential diagnoses include hippocampal sclerosis with TDP-43, primary age-related tauopathy, argyrophilic grain disease, frontotemporal lobar degeneration, Lewy body disease, chronic traumatic encephalopathy as well as nondegenerative disorders such as cerebrovascular disease, chronic alcohol consumption, limbic encephalitis, medial temporal lobe epilepsy, and others.
|
30925614 |
2019 |
|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although AD with TDP-43/Hippocampal sclerosis pathology was greater in number in women than men, the difference was not significant after adjustments for age at death and other confounders.
|
31128096 |
2019 |
|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The neuropathologic traits of interest were pathologic AD according to modified NIA-Reagan criteria, three quantitative measures of AD pathology (global AD pathology score, β-amyloid load and PHFtau tangle density), macro- and micro-scopic infarcts, neocortical Lewy bodies, TDP-43 and hippocampal sclerosis.
|
31269985 |
2019 |
|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The importance of the pathways varied, with the vascular pathway accounting for 32% of the association between age and dementia, wheraes the remaining three inter-related degenerative pathways together accounted for 68% (amyloid/tau, 24%; the Lewy body, 1%; and TDP-43/hippocampal sclerosis, 43%).
|
29944741 |
2018 |
|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
For the autopsy cohort, sequential cases with antemortem 18F-FDG-PET were screened and those with TDP-43-negative Alzheimer's disease (10 cases) and TDP-43-positive hippocampal sclerosis (eight cases) were included.
|
29538658 |
2018 |
|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amyloid-β, paired helical filament tau, Lewy bodies, TDP-43, and hippocampal sclerosis were microscopically evaluated in the midbrain, medial temporal, and neocortical regions that capture the progression of each neuropathology.
|
30093249 |
2018 |
|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the NS, there was a significant association between cognitive performance and TDP-43 (OR 1.94 p = 0.005, 95% CI 1.22-3.09) (HS remained significant, but AD did not).
|
30452409 |
2018 |
|
Hippocampal sclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dementia (p < 0.001) and TDP-43 immunopositivity of the granular cell layer of the dentate fascia (p < 0.001) were strongly associated with HS.
|
29614661 |
2018 |
|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We fit structural equation models to map the association between APOE and TDP-43, Aβ, and tau, accounting for age and hippocampal sclerosis.
|
30422173 |
2018 |
|
Hippocampal sclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The diagnosis of Alzheimer's disease (AD) in the oldest-old is complicated by the increasing prevalence of age-related neurofibrillary tangles, plaques and non-AD pathologies such as cerebrovascular disease (CVD), hippocampal sclerosis (HS), aging-related tau astrogliopathy (ARTAG), as well as TDP-43 and Lewy pathology.
|
29916037 |
2018 |
|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent discoveries have prompted a conceptual expansion of hippocampal sclerosis of aging because (1) cellular inclusions of TAR DNA-binding protein 43 kDa (TDP-43) are frequent; (2) TDP-43 pathology may be found outside hippocampus; and (3) brain arteriolosclerosis is a common, possibly pathogenic, component.
|
28467211 |
2017 |
|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vascular pathology, Lewy bodies, TDP-43, and hippocampal sclerosis are frequent comorbidities.
|
28282807 |
2017 |
|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Four cases had pathologically confirmed CTE; concomitant pathologies included Alzheimer's disease (N = 6), TDP-43 (N = 6), cerebral amyloid angiopathy (N = 5), hippocampal sclerosis (N = 2), corticobasal degeneration (N = 1), dementia with Lewy bodies (N = 1), and vascular pathology (N = 1); and all would have contributed synergistically to the clinical manifestations.
|
28205009 |
2017 |
|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of the 15 with TDP-43, three showed a moderate number of inclusions and also had hippocampal sclerosis, neuronal intranuclear inclusions and fine neurites of the CA1 region of the hippocampus.
|
28160067 |
2017 |
|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, the severity of TDP-43-positive fine neurites in CA1 sector, a possible pathologic precursor of HpScl, was associated with the TMEM106B variant.
|
25367383 |
2015 |
|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abnormal neuronal accumulation and modification of TAR DNA binding protein 43 (TDP-43) have recently been discovered to be defining histopathological features of particular subtypes of frontotemporal dementia and amyotrophic lateral sclerosis, and are also common in aging, particularly coexisting with hippocampal sclerosis and Alzheimer's disease pathology.
|
24927705 |
2014 |
|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, we determined whether the effects of TDP-43 were mediated by hippocampal sclerosis.
|
24659241 |
2014 |
|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autopsy showed hippocampal sclerosis with TDP-43 immunoreactive neuronal inclusions relatively limited to limbic lobe structures.
|
23922030 |
2013 |
|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We quantified the neuronal cytoplasmic inclusions, glial inclusions, neuronal intranuclear inclusions, dystrophic neurites, surviving neurones, abnormally enlarged neurones, and vacuoles in regions of the frontal and temporal lobe using a phosphorylation-independent TDP-43 antibody in 32 cases of FTLD-TDP comprising sporadic and familial cases, with associated pathology such as hippocampal sclerosis (HS) or Alzheimer's disease (AD), and four neuropathological subtypes using TDP-43 immunohistochemistry.
|
21696412 |
2012 |
|
Hippocampal sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age, hippocampal sclerosis and clinical phenotype.
|
21968532 |
2011 |
|
Hippocampal sclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results suggest that a genetic variant in GRN leading to decreased levels of progranulin may be a risk factor for HpScl in AD, while its role in TDP-43 immunoreactivity in AD remains less certain.
|
20197700 |
2010 |